NIH grant supports AI development for glaucoma prognosis and care

The National Eye Institute (NEI) and National Institutes of Health (NIH) awarded Mingquan Lin, PhD, an assistant professor in the Division of Computational Health Sciences at the University of Minnesota Medical School, a 5-year, $3.7 million grant for his research on Developing Robust Multimodal AI for Primary Open-Angle Glaucoma Prognosis.

This award will support the development of trustworthy AI technologies for ophthalmology and help advance earlier identification of patients at high risk for vision loss.

Primary open-angle glaucoma is a leading cause of irreversible blindness worldwide. This project aims to develop robust multimodal AI models that integrate fundus photography, OCT, visual field testing, and clinical data to predict glaucoma progression and support clinical decision-making. The project emphasizes both predictive performance and clinical usability to facilitate real-world implementation.

This project aims to develop clinically deployable AI systems that can help ophthalmologists identify patients at high risk of glaucoma progression earlier and more accurately. Our goal is to improve patient outcomes while ensuring that AI tools are robust, trustworthy, and practical for real-world clinical use."

Dr. Mingquan Lin, PhD, assistant professor, Division of Computational Health Sciences, University of Minnesota Medical School

The project involves collaborations among investigators at the University of Minnesota, Weill Cornell Medicine, and Washington University in St. Louis.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Popular diabetes drugs do not alter the risk of developing a blinding eye condition